The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice

Magnetic Resonance in Medicine

Volumn 64, Issue 5, 2010, Pages 1274-1280

  Wadas, Thaddeus J ^a   Sherman, Christopher D ^a   Miner, Jeffrey H ^a   Duncan, James R ^a   Anderson, Carolyn J ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Alport syndrome; Gadolinium; Magnetic resonance imaging; Nephrogenic systemic fibrosis

Indexed keywords

GADOLINIUM; MAGNETIC RESONANCE IMAGING; MAMMALS;

ALPORT SYNDROME; BIODISTRIBUTIONS; CONTRAST-ENHANCED MR; CRITICAL FACTORS; KIDNEY FUNCTION; MAGNETIC RESONANCE CONTRAST AGENTS; NEPHROGENIC SYSTEMIC FIBROSIS; TISSUE DISTRIBUTIONS;

TISSUE;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GD 153; 2,2',2'',2''' [2,2' (CARBOXYMETHYLAZANEDIYL) BIS(ETHANE 2,1 DIYL)BIS(AZANETRIYL)]TETRAACETIC ACID GD 153; 5,8 BIS(CARBOXYMETHYL) 2 [2(METHYLAMINO) 2 OXOETHYL] 10 OXO 2,5,8,11 TETRAAZADODECANE 1 CARBOXYLIC ACID GD 153; TRACER; UNCLASSIFIED DRUG; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE TISSUE; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; KIDNEY FAILURE; KIDNEY FUNCTION; MOUSE; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TISSUE DISTRIBUTION; UREA NITROGEN BLOOD LEVEL; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; HUMAN; METABOLISM; NEPHRITIS; PATHOLOGY; SPECIES DIFFERENCE; TRANSGENIC MOUSE;

ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GADOLINIUM; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEPHRITIS, HEREDITARY; ORGAN SPECIFICITY; RENAL INSUFFICIENCY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 78349253807     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22553     Document Type: Article

References (35)

1. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ,. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008; 43: 65-75.
2. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE,. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
3. Cowper SE,. Available at: Nephrogenic fibrosing dermopathy [NFD/NSF Website] 2001-2009. Accessed September 10, 2009.
4. Grobner T, Prischl FC,. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007; 72: 260-264.
5. Bhave G, Lewis JB, Chang SS,. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008; 180: 830-835.
6. Swaminathan S, Shah SV,. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007; 18: 2636-2643.
7. Deo A, Fogel M, Cowper SE,. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 264-267.
8. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS,. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362.
9. Port M, Idee J-M, Medina C, Robic C, Sabatou M, Corot C,. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. BioMetals 2008; 21: 469-490.
10. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann H-J, Pietsch H,. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008; 18: 2164-2173.
11. Edward M, Quinn JA, Mukherjee S, Jensen MBV, Jardine AG, Mark PB, Burden AD,. Gadodiamide contrast agent activates fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008; 214: 584-593.
12. Hewitson TD, Ono T, Becker GJ,. Small animal models of kidney disease: a review. Methods Mol Biol 2009; 466: 41-57.
13. Dai C, Kiss L, Liu Y,. Animal models of kidney disease. In:, Conn P, editor. Sourcebook of Models for Biomedical Research. Totowa, NJ: Humanna Press, Inc.; 2008. 657 p.
14. Andrews KL, Mudd JL, Li C, Miner JH,. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 2002; 160: 721-730.
15. Cosgrove D, Kalluri R, Miner JH, Segal Y, Borza DB,. Choosing a mouse model to study the molecular pathobiology of Alport glomerulonephritis. Kidney Int 2007; 71: 615-618.
16. Miner JH, Sanes JR,. Molecular and functional defects in kidneys of mice lacking collagen I±3(IV): implications for Alport syndrome. J Cell Biol 1996; 135: 1403-1413.
17. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, Anderson CJ,. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004; 47: 1465-1474.
18. Sun X, Wuest M, Weisman GR, Wong EH, Reed DP, Boswell CA, Motekaitis R, Martell AE, Welch MJ, Anderson CJ,. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 2002; 45: 469-477.
19. 64Cu-labeled RGD peptide. J Nucl Med 2007; 48: 311-318.
20. Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, Anderson CJ,. Preparation and biological evaluation of copper-64-labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 2004; 10: 8674-8682.
21. 64Cu-labeled somatostatin analogs in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 1999; 42: 1341-1347.
22. Beilvert A, Cormode DP, Chaubet F, Briley-Saebo K, Mani V, Mulder WJM, Vucic E, Toussaint JF, Letourneur D, Fayad ZA,. Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque. Magn Reson Med 2009; 62: 1195-1201.
23. Mulder WJM, Strijkers GJ, Briley-Saboe KC, Frias JC, JGS A, Vucic E, Amirbekian V, Tang C, Chin PTK, Nicolay K, Fayad ZA,. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med 2007; 58: 1164-1170.
24. Constantinidis I, Grant S, Simpson NE, Oca-Cossio JA, Sweeney CA, Mao H, Blackband SJ, Sambanis A,. Use of magnetic nanoparticles to monitor alginate-encapsulated betaTC-tet cells. Magn Reson Med 2009; 61: 282-290.
25. Feng Y, Jeong EK, Mohs AM, Emerson L, Lu ZR,. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice. Magn Reson Med 2008; 60: 1347-1352.
26. Tweedle MF, Wedeking P, Kumar K,. Biodistribution of radiolabled, formulated gadopentetate, gadoteriol, gadoterate and gadodiamide in mice and rats. Invest Radiol 1995; 30: 372-380.
27. Tweedle MF,. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992; 27 (Suppl. 1): 2-6.
28. Abraham JL, Thakral C,. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 2008; 66: 200-207.
29. Zak O, Aisen P,. Spectroscopic and thermodynamic studies on the binding of gadolinium(III) to human serum transferrin. Biochemistry 1988; 27: 1075-1080.
30. Bass LA, Wang M, Welch MJ, Anderson CJ,. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjugate Chem 2000; 11: 527-532.
31. Franano FN, Edwards WB, Welch MJ, Brechbiel MW, Gansow OA, Duncan JR,. Biodistribution and metabolism of targeted and nontargeted protein-chelate- gadolinium complexes: evidence for gadolinium dissociation in vitro and in vivo. Magn Reson Imaging 1995; 13: 201-214.
32. Hocine N, Berry JP, Jaafoura H, Escaig F, Masse R, Galle P,. Subcellular localization of gadolinium injected as soluble salt in rats: a microanalytical study. Cell Mol Biol 1995; 41: 271-278.
33. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Campbell ME, Hauschkac PV, Hannigand RE,. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 2009; 1: 479-488.
34. Frenzel T, Lengsfeld P, Schirmer H, Huetter J, Weinmann H-J,. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol 2008; 43: 817-828.
35. Anderson CJ,. Metabolism of radiometal-labeled proteins and peptides: what are the real radiopharmaceuticals in vivo? Cancer Biother Radiopharm 2001; 16: 451-455.